[8-K] Fortinet, Inc. Reports Material Event

Rhea-AI Filing Summary

Artiva Biotherapeutics (ARTV) filed a Form 8-K on August 6, 2025. Under Item 2.02, the company disclosed that it issued a press release announcing financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is expressly not deemed “filed” for liability purposes under Section 18 of the Exchange Act. Item 9.01 lists the exhibits included in the filing, namely the press release and the cover-page Inline XBRL data file. No actual financial figures, guidance, or narrative commentary are contained within the 8-K itself.

The filing is procedural, serving mainly to make the earnings release publicly available while limiting legal exposure. Investors must review Exhibit 99.1 for quantitative details.

Insights

Securities Analyst

TL;DR: Routine 8-K furnishes Q2-25 earnings release; no numbers disclosed here.

The 8-K is purely administrative, triggering no immediate valuation insight because it omits the underlying financial metrics. Management uses Item 2.02 to ensure Reg FD compliance while keeping the furnished material outside Section 18 liability. Impact on the stock will depend entirely on the content of Exhibit 99.1, which is not provided. Therefore, the filing itself is neutral and non-impactful from an analytical standpoint.

0001262039false00012620392025-08-062025-08-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 6, 2025

 FORTINET, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-34511

77-0560389

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

909 Kifer Road

Sunnyvale, CA 94086

(Address of principal executive offices, including zip code)

(408) 235-7700

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

(Title of each class)

(Trading Symbol)

(Name of exchange on which registered)

Common Stock, $0.001 Par Value

FTNT

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   

Emerging growth company    ☐ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐ 

Item 2.02 Results of Operations and Financial Condition.

On August 6, 2025, Fortinet, Inc. issued a press release reporting its financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press release dated August 6, 2025
104						Cover Page Interactive Data File - the cover page for this Current Report on Form 8-K is formatted in iXBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Fortinet, Inc.
Date: August 6, 2025			By:			/s/    JOHN WHITTLE
						John Whittle
						Chief Operating Officer

FAQ

Why did Artiva Biotherapeutics (ARTV) file a Form 8-K on August 6, 2025?

To furnish its press release announcing financial results for the quarter ended June 30, 2025 under Item 2.02.

Does the 8-K include Artiva’s Q2 2025 financial numbers?

No. The filing references the press release as Exhibit 99.1, but no figures appear in the body of the 8-K.

Is the furnished press release considered "filed" with the SEC?

No. Artiva states the information is not deemed "filed" for purposes of Section 18 of the Exchange Act.

What exhibits accompany the 8-K?

Exhibit 99.1 (press release dated August 6, 2025) and Exhibit 104 (cover-page Inline XBRL data file).

How should investors obtain the actual earnings details?

Investors need to read Exhibit 99.1, which contains the full Q2 2025 financial results.